Full Press Release Details
SAN RAFAEL, Calif. , Oct. 11, 2017 /PRNewswire/ --
Key program updates will include the following:
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) will host an R&D Day from 8am (ET) to 1pm (ET) on Wednesday, October 18, 2017 in New York City . BioMarin management and external experts will provide an update to the investment community on the Company's development portfolio, which is focused on innovative therapies to treat rare and ultra-rare diseases.
External key opinion leaders scheduled to present include:
Maureen Cleary , M.D., F.R.C.P.C.H., Consultant in Inherited Metabolic Disease and Senior Lecturer at Institute of Child Health at Great Ormond Street Hospital for Children
Nicola Longo , M.D., Ph.D., Professor of Pediatrics and Adjunct Professor of Pathology at the University of Utah
Steven Pipe , M.D., Pediatric hematologist; Laurence A. Boxer Research Professor of Pediatrics and Communicable Disease, as well as Professor of Pathology at the University of Michigan
BioMarin speakers scheduled to present include:
Jean-Jacques Bienaimé, Chairman and Chief Executive Officer Hank Fuchs , M.D., President, Worldwide Research & Development Robert Baffi , Ph.D., Executive Vice President, Technical Operations Geoff Nichol , M.B., Ch.B., M.B.A., Senior Vice President, Chief Medical Officer and Head of Global Clinical Development David Jacoby , M.D., Ph.D., Executive Group Medical Director Adam Shaywitz , M.D., Ph.D., Executive Medical Director, Clinical Science Ben Kim , M.D., M.Phil., Senior Medical Director, BMN 270 Steve Maricich , M.D., Ph.D., Medical Director, Clinical Science
Live Video Webcast Interested parties may access a live video webcast that will include audio and slides of the presentations via the investor section of the BioMarin website, www.biomarin.com . A replay of the meeting will be archived on the site for at least one week.
For those who choose not to listen and view the event via webcast, dial-in information for the audio portion of the webcast can be accessed using:
U.S. / Canada Dial-in Number: (800) 319-9003 International Dial-in Number: (719) 325-3302 Conference ID: 138108
About BioMarin BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.biomarin.com . Information on BioMarin's website is not incorporated by reference into this press release.
| Contacts: | |
| Investors | Media |
| Traci McCarty | Debra Charlesworth |
| BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. |
| (415) 455-7558 | (415) 455-7451 |
SOURCE BioMarin Pharmaceutical Inc.